Advertiser profiles

BD Medical– Ben Venue Laboratories BENEO-Palatinit GmbH

Pharmaceutical PO Box 46568 Gottlieb-Daimler-Strasse 12
Systems Bedford, OH 44146 68165 Mannheim, Germany
tel. 440.232.3320 tel. +49 621 421 150
1 Becton Dr. fax +49 621 421 160
fax 440.439.6398
Franklin Lakes, NJ 07417 galeniq@beneo-palatinit.com
peter.hansbury@
tel. 800.225.3310 www.galeniq.com
boehringer-ingelheim.com
fax 201.847.4847 www.benvenue.com
BDPS_marketing@bd.com
www.bd.com/pharmaceuticals

Description Description
Ben Venue Laboratories develops BENEO-Palatinit is a 100% sub-
Description sidiary of Südzucker AG. As a
and manufactures sterile liquid and
BD Medical–Pharmaceutical member of IPEC, BENEO-Palatinit
lyophilized products under contract.
Systems is dedicated to devel- is implementing under IPEC–GMP
The company has expertise in han-
oping prefillable drug-delivery conditions for bulk pharmaceuti-
dling complex formulations and has
systems designed to fit the needs cal excipients. BENEO-Palatinit is
contributed to the creation of many
of the pharmaceutical industry. showing its multifunctional sugar-
significant pharmaceutical products
BD offers a range of products, free excipient galenIQ. Based on
for nearly 70 years. Products from
including glass and plastic pre- hydrogenated isomaltulose and
Ben Venue Laboratories are distrib-
fillable syringes, a nasal-spray its refined modifications, galenIQ
uted globally. Ben Venue Laborato-
system, and various self-injection is offered in different grades for
ries is a wholly owned subsidiary of
devices. Each of these differenti- solid dosage forms.
Boehringer Ingelheim Corporation.
ates pharmaceutical products
and contributes to the optimi- Products and services
Products and services
zation of drug therapy. All the galenIQ from BENEO-Palatinit is a
• Dedicated cytotoxic and geno-
company’s prefillable devices range of bulk excipients, including
toxic manufacturing facility
are designed to meet health- tailor-made grades for oral solid
opening Q2 2009
care professionals’ demands for dosage forms. Excellent alterna-
• Phase I to commercial on-site
safety and convenience and to tives for direct compression, cap-
production in batch sizes from
fulfill patients’ needs for comfort. sule-filling, or powder-mixture ap-
1 L to 2000 L
BD’s worldwide presence, market plications present galenIQ grades
• Liquid or lyophilized sterile
awareness, and pharmaceuti- 720 and 721. The galenIQ 800
products
cal packaging know-how allow series additionally offers special
• Centrally located 500,000-ft2
the company to propose suitable powder grades for wet granula-
manufacturing facility
solutions for all regional markets tion, compaction, and other ag-
• Largest contract sterile-
and parenteral drug-delivery glomeration processes.
injectable lyophilization capacity
needs. in the world
AAPS Booth 504
• Expertise in manufacturing
AAPS Booth 1443 complex formulations—micro-
spheres, liposomes, emulsions,
and nanotechnology
• Global product distribution.
AAPS Booth 1949
130 Pharmaceutical Technology  NOVEMBER 2008 pharmtech.com